ccnq Antibody

What is the CCN family and why are antibodies against these proteins important?

The CCN family consists of matricellular proteins with diverse biological functions. CCN1 (also known as CYR61) promotes cell proliferation, chemotaxis, angiogenesis, and cell adhesion, and plays significant roles in wound healing . These proteins have a conserved multimodular structure consisting of four domains: insulin-like growth factor binding protein (IGFBP), von Willebrand factor type C (VWC), thrombospondin type 1 (TSP1), and a C-terminal (CT) module .

Antibodies against CCN proteins are essential tools for understanding their expression patterns, localization, and functional roles in normal and pathological conditions. They enable detection of both full-length and truncated protein variants, which is critical since post-translational processing can generate multiple CCN protein species with potentially distinct functions .

What applications are CCN antibodies suitable for?

CCN antibodies are versatile research tools applicable to multiple experimental techniques:

The selection of the appropriate antibody depends on the specific experimental goals. For instance, rabbit polyclonal CCN1 antibody has been validated for Western blotting, immunohistochemistry on paraffin-embedded sections (IHC-P), and immunocytochemistry/immunofluorescence (ICC/IF) . In contrast, recombinant monoclonal human IgG antibodies against CCN1 have been optimized for ELISA, flow cytometry, and functional assays .

How should researchers optimize antibody dilutions for different applications?

For applications like ELISA and flow cytometry, manufacturers recommend that "optimal dilutions of this antibody should be experimentally determined" . This typically involves testing a range of concentrations (often in 2-fold or 5-fold dilution series) to identify the dilution that produces the highest signal-to-background ratio.

Module-specific antibodies may require different concentrations for optimal results. For example, in one study, anti-NH5 antibody (targeting the CT module) showed higher sensitivity than other module-specific antibodies, requiring lower concentrations for equivalent detection .

How can domain-specific antibodies be used to characterize CCN protein variants?

Domain-specific antibodies are powerful tools for identifying and characterizing full-length and truncated CCN proteins. For CCN3, researchers have developed module-specific antibodies (anti-NH2, -NH3, -NH4, and -NH5) that recognize the IGFBP, VWC, TSP1, and CT modules, respectively .

These antibodies enable the detection of specific structural domains within CCN proteins under both native and denaturing conditions. For example, in studies of CCN3:

• Anti-NH2 antibodies detect only proteins containing the IGFBP module

• Anti-NH3 recognizes proteins with the VWC module

• Anti-NH4 identifies proteins containing the TSP1 module

• Anti-NH5 detects proteins with the intact CT module

By using combinations of these domain-specific antibodies, researchers can determine the structural composition of CCN protein variants expressed in biological samples. This approach is particularly valuable for identifying post-translationally processed forms that may have altered biological activities.

What are the considerations for validating antibody specificity against CCN proteins?

Validating antibody specificity is crucial for accurate interpretation of experimental results. For CCN proteins, consider these approaches:

• Cross-reactivity testing: Confirm that module-specific antibodies only recognize their target module and do not cross-react with other modules. For example, anti-NH antibodies raised against one CCN3 module should not react with other modules .

• Control samples: Use recombinant proteins containing defined combinations of modules as positive and negative controls. For instance, testing anti-NH2 antibodies against sMNH24 (containing the IGFBP module) and sMNH35 (lacking the IGFBP module) can confirm specificity .

• Multiple detection methods: Validate antibody performance across different techniques (Western blot, immunofluorescence, immunohistochemistry) to ensure consistent recognition of target proteins .

• Knockout or knockdown validation: When possible, use cells or tissues with reduced or eliminated expression of the target protein to confirm antibody specificity.

What strategies can researchers employ to detect native versus denatured forms of CCN proteins?

The detection of native versus denatured CCN proteins requires careful consideration of antibody properties and experimental conditions:

• Native conditions:

  • Immunoprecipitation using module-specific antibodies can capture native CCN proteins

  • Flow cytometry can detect cell surface-associated CCN proteins in their native conformation

  • ELISA using capturing and detecting antibodies that recognize different epitopes

• Denaturing conditions:

  • Western blotting with SDS-PAGE separates proteins based on molecular weight

  • Immunohistochemistry on fixed tissues often involves partial denaturation of proteins

Some antibodies may preferentially recognize either native or denatured forms. For example, anti-K19M antibody (targeting C-terminal amino acids of CCN3) does not efficiently recognize the native protein, suggesting that the C-terminus may be inaccessible due to structural constraints or interactions with other partners . In contrast, anti-NH5 antibody readily detects the CT domain in both native and denatured forms .

How can researchers troubleshoot variable detection sensitivity with different domain-specific antibodies?

Variable detection sensitivity is a common challenge when working with domain-specific antibodies. Researchers have observed that different module-specific antibodies show different sensitivities, requiring adjustment of IgG concentrations for optimal detection . Consider these troubleshooting approaches:

• Adjust antibody concentration: Domain-specific antibodies may require different working concentrations. For example, anti-NH5 (targeting the CT module of CCN3) typically shows higher sensitivity than other module-specific antibodies .

• Optimize blocking conditions: Test different blocking agents (BSA, milk, serum) to reduce background while maintaining specific signal.

• Consider epitope accessibility: Some domains may be less accessible in certain protein conformations or complexes. The VWC module of CCN3, for example, appears to be a weaker immunogen, resulting in less robust detection with anti-NH3 antibodies .

• Evaluate protein expression levels: Weak signals may reflect low abundance rather than antibody issues. Compare results with positive controls expressing known quantities of target protein.

• Check for post-translational modifications: Modifications can affect epitope recognition. High molecular weight bands detected by anti-NH5 antibodies may represent oligomerization driven by the CT module .

What are the recommended protocols for producing and purifying domain-specific CCN antibodies?

Based on published methodologies for generating domain-specific CCN3 antibodies, researchers can follow these key steps:

• Construct design: Clone individual CCN protein domains into expression vectors (e.g., pGEX) to create GST fusion proteins .

• Bacterial expression: Transform E. coli BL21 cells with the expression constructs and induce protein production .

• Protein purification: Purify fusion proteins by affinity chromatography (e.g., glutathione-Sepharose beads) .

• Quality control: Confirm purity by Coomassie blue staining of SDS-PAGE gels .

• Immunization: Inject purified fusion proteins into rabbits (typically 1.5 mg total protein per rabbit) .

• Antibody purification: Purify IgGs from rabbit sera using affinity chromatography, with typical yields ranging from 3.8-12 mg/ml depending on the immunogenicity of the domain .

• Validation: Test antibody specificity against recombinant proteins and cellular extracts .

What are the optimal conditions for detecting CCN proteins by Western blotting?

For optimal Western blot detection of CCN proteins, consider these technical parameters:

• Sample preparation: Use appropriate lysis buffers that maintain protein integrity while ensuring complete extraction. For secreted CCN proteins, analyze conditioned media in addition to cell lysates .

• Gel selection: 10% SDS-PAGE gels are suitable for resolving CCN proteins, which typically range from 30-60 kDa .

• Protein loading: Load 20-30 μg of whole cell extract per lane for cell lysates .

• Transfer conditions: Optimize transfer time and voltage based on protein size.

• Blocking: 5% non-fat milk or BSA in TBST is typically effective.

• Antibody dilution: For anti-CYR61/CCN1 antibody (ab228592), use a 1/1000 dilution . Adjust concentrations for other antibodies based on their specific sensitivities.

• Detection system: Choose chemiluminescence or fluorescence-based detection systems based on required sensitivity.

• Expected bands: Full-length CCN1/CYR61 appears at approximately 54 kDa, while truncated forms may appear at lower molecular weights (e.g., 32 kDa) .

How can immunofluorescence and immunohistochemistry protocols be optimized for CCN protein detection?

For effective immunolocalization of CCN proteins in cells and tissues:

• Fixation: Select appropriate fixatives (paraformaldehyde for immunofluorescence, formalin for paraffin embedding) that preserve antigenic epitopes.

• Antigen retrieval: For paraffin sections, optimize antigen retrieval methods (heat-induced, enzymatic) to expose epitopes without damaging tissue architecture.

• Blocking: Use serum from the species in which the secondary antibody was raised to minimize non-specific binding.

• Primary antibody incubation: Optimize concentration and incubation time/temperature. Domain-specific antibodies have been successfully used for both immunofluorescence and immunohistochemistry on paraffin-embedded sections .

• Controls: Include positive controls (cells/tissues known to express the target protein) and negative controls (omitting primary antibody).

• Signal amplification: Consider tyramide signal amplification or other methods for detecting low-abundance proteins.

• Analysis considerations: Be aware that different module-specific antibodies may show different staining patterns depending on the presence of full-length versus truncated protein forms .

How can CCN antibodies be utilized for analyzing protein-protein interactions?

CCN proteins function through interactions with various binding partners including integrins, heparin, and growth factors. Antibodies can be valuable tools for studying these interactions:

• Co-immunoprecipitation: Domain-specific antibodies can be used to pull down CCN proteins and identify associated proteins. Since these antibodies recognize native proteins, they can preserve physiologically relevant interactions .

• Proximity ligation assays: Combining CCN antibodies with antibodies against potential interaction partners can visualize protein-protein interactions in situ.

• Functional blocking: Some antibodies may block specific protein domains, allowing researchers to determine which domains are required for particular protein-protein interactions.

• Domain mapping: By using domain-specific antibodies in combination with mutated proteins, researchers can map interaction domains with precision.

Consider that CCN1-mediated gene regulation is dependent on heparin-binding, and the protein promotes specific cellular functions through interactions with different integrins: adhesion through integrin α6/β1, migration through integrin αv/β5, and proliferation through integrin αv/β3 .

What are the emerging applications of CCN antibodies in cancer research?

CCN proteins have been implicated in various cancers, making CCN antibodies valuable tools for oncology research:

• Tumor profiling: Domain-specific antibodies enable detailed characterization of CCN protein expression in tumor samples, potentially identifying truncated variants with altered functions .

• Biomarker development: CCN proteins may serve as diagnostic or prognostic biomarkers in certain cancers. For example, CCN3 expression has been analyzed in osteosarcomas and Ewing's sarcomas .

• Therapeutic targeting: Understanding the structural domains of CCN proteins involved in cancer progression could guide the development of therapeutic antibodies that block specific functions.

• Mechanistic studies: Antibodies that recognize specific domains can help elucidate the mechanisms by which CCN proteins contribute to cancer cell proliferation, migration, and angiogenesis.

The set of module-specific antibodies against CCN3 has been described as "unique tools to undertake wide screening of CCN3 expression in tumor arrays" and potentially useful for proteomic analysis .